Figure 6.
In vivo evaluation of the combinatorial effect of Lupeol and 5FU in a TNBC syngeneic mice model
(A) Schematic representation of dosing schedule (all compounds were administered intraperitoneally).
(B) In vivo live animal images of the 4T1luc2 induced tumors in various treatment arms in BALB/c mice at day 5 (initiation of treatment) and at day 15 (experimentation endpoint).
(C) Graph representing the log of average radiance vs. Time of the tumor growth.
(D) Representative photomicrograph of freshly harvested breast tumors with a ruler (below) for scale.
(E) Graph representing the tumor volume vs. the various treatment arms.
(F) Representative images of Hematoxylin and Eosin stain followed by IHC staining for Ki67 and Caspase 3c in the sections of harvested tumors developed in BALB/c mice along with their quantitative graphs.
(G) Representative images of the IHC staining to evaluate the differential expression of phospho-EphA2 and phospho-cMET in the tumors of the various treatment arms along with their quantitative graphs. ∗p < 0.05 and ∗∗∗p < 0.001 statistically significant difference compared to corresponding control by one-way ANOVA. Data are representative of triplicate experiments (mean ± SD) ns = not significant; HGF = hepatocyte growth factor; HF = HGF+5FU; HL = HGF+Lupeol; HFL = HGF+5FU + Lupeol. Scale bars: 200 μm. Also see, Figure S6 and Table S8.